modernretina.com

Revisión web de modernretina.com

Modern Retina – Ophthalmology News, Events & Expert Insights

 Generado el 31 Marzo 2026 15:12 PM

Resultados antiguos? ACTUALIZAR !

La puntuación es 57/100

Contenido SEO

Título

Modern Retina – Ophthalmology News, Events & Expert Insights

Longitud : 60

Perfecto, tu título contiene entre 10 y 70 caracteres.

Descripción

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Longitud : 155

Genial, tu descripción meta contiene entre 70 y 160 caracteres.

Palabras Claves (Keywords)

Muy mal. No hemos encontrado palabras clave (meta keywords) en tu página. Usa este generador de meta tags gratuito para crear tus palabras clave.

Propiedades Meta Og

Bien. Tu página usa propiedades Og (etiquetas og).

Propiedad Contenido
title Modern Retina
type website
image https://www.modernretina.com/MR_Hover_Logo.jpg
url https://www.modernretina.com/
image:url https://www.modernretina.com/MR_Hover_Logo.jpg
image:width 1200
image:height 630
image:alt Modern Retina – Ophthalmology News, Events & Expert Insights

Titulos

H1 H2 H3 H4 H5 H6
1 56 46 4 16 0
  • [H1] Latest News
  • [H2] Conference Coverage
  • [H2] Trending on Modern Retina
  • [H2] Shorts
  • [H2] Podcasts
  • [H2] Videos
  • [H2] Modern Retina Digital Edition
  • [H2] Continuing Medical Education
  • [H2] (CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] (COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] (CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] Practical Approaches to Modern Dry Eye Treatment and Management
  • [H2] (COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] 20th Annual Controversies in Modern Eye Care
  • [H2] (CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] (COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Collaborative Care Symposium
  • [H2] Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
  • [H2] (CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] (COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop
  • [H2] (COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] (CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] Interventional Dry Eye: A Stepwise Treatment & Management Approach
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] (CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
  • [H2] (CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
  • [H2] (CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
  • [H2] (CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
  • [H2] All News
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
  • [H3] The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD
  • [H3] Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
  • [H3] The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
  • [H3] PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
  • [H3] PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
  • [H3] Integrating AI to manage DR in a primary care setting
  • [H3] What to expect from virtual AAO 2020
  • [H3] Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
  • [H3] Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
  • [H3] Ophthalmic drug shortages more frequent, longer lasting than average
  • [H3] Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
  • [H3] FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
  • [H3] Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa
  • [H3] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H3] Q&A: AI-predicted retinal function shows promise in geographic atrophy
  • [H3] Dr. Mali’s top 5 predictions in ophthalmology for 2026
  • [H3] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H3] Q&A: Gennady Landa, MD, shares clinical insights on the ranibizumab ocular implant
  • [H3] Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar
  • [H3] ISS 2026 highlights advances in ophthalmic imaging for retinal practice
  • [H3] American College of Physicians policy paper urges medical community to drop the term “'provider"
  • [H3] PRIMA System: A major step in the battle against GA
  • [H3] MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
  • [H3] Metformin use associated with reduced incidence of intermediate AMD
  • [H3] FDA decision: Carbachol–brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results
  • [H3] New optoretinography technique allows direct measurement of rod function in vivo
  • [H3] Navigating geographic atrophy from biomarkers to bilateral therapy
  • [H3] Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Long-lived Greenland sharks may point to new approaches for retinal disease
  • [H3] Molecular insights and clinical experience: Extending anti-VEGF durability
  • [H3] Q&A: Evolving approaches to geographic atrophy management
  • [H3] Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
  • [H3] Rates of retinal layer thinning predict visual field progression in glaucoma
  • [H3] First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
  • [H3] FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
  • [H3] 8 things to know about aflibercept 8 mg for retinal vascular disease
  • [H3] A new treatment round-up for AMD and GA
  • [H4] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H4] Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months
  • [H4] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H4] ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
  • [H5] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H5] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H5] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H5] Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
  • [H5] The Retina TL;DR with Dr. Weng: Targeting the Fas signaling pathway with David Zacks, MD, PhD
  • [H5] Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases
  • [H5] Management Approaches for Suboptimal Responders in AMD, DME, and RVO
  • [H5] Comparing Aflibercept 8 mg and Faricimab in RVO
  • [H5] Insights from Privotal Trials for Aflibercept (8 mg) in RVO
  • [H5] Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
  • [H5] Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases
  • [H5] Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
  • [H5] Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
  • [H5] Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
  • [H5] Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
  • [H5] Evaluating Progressive Multifocal Geographic Atrophy in an Asymptomatic 81-Year-Old Male

Imagenes

Hemos encontrado 135 imágenes en esta web.

23 atributos alt están vacios o no existen. Agrega texto alternativo para que los motores de búsqueda puedan entender las imágenes.

Ratio Texto/HTML

Ratio : 3%

El ratio entre texto y código HTML de esta página es menor que el 15 por ciento, esto significa que tu web posiblemente necesite más contenido en texto.

Flash

Perfecto, no se ha detectado contenido Flash en la página.

Iframe

Genial, no se han detectado Iframes en la página.

Reescritura URL

Bien. Tus enlaces parecen amigables

Guiones bajos en las URLs

Perfecto! No hemos detectado guiones bajos en tus URLs

Enlaces en página

Hemos encontrado un total de 89 enlaces incluyendo 0 enlace(s) a ficheros

Ancla Tipo Jugo
All News Interna Pasando Jugo
Blogs Interna Pasando Jugo
All Videos Interna Pasando Jugo
Case-Based Roundtable Series Interna Pasando Jugo
Eichenbaum Acorns Interna Pasando Jugo
Expert Interviews Interna Pasando Jugo
Eyeviews Interna Pasando Jugo
Insights Interna Pasando Jugo
Medical World News Externo Pasando Jugo
Podcasts Interna Pasando Jugo
Rapid Readouts Interna Pasando Jugo
The Retina TL;DR Interna Pasando Jugo
Viewpoints Interna Pasando Jugo
Conference Coverage Interna Pasando Jugo
Conference Listing Interna Pasando Jugo
Modern Retina Digital Edition Interna Pasando Jugo
Supplements And Featured Publications Interna Pasando Jugo
Between the Lines Interna Pasando Jugo
CME/CE Interna Pasando Jugo
EYLEA 8mg for nAMD and DME Treatment Interna Pasando Jugo
Sponsored Resources Interna Pasando Jugo
Partners Interna Pasando Jugo
Subscribe Interna Pasando Jugo
AMD Interna Pasando Jugo
Wet AMD Interna Pasando Jugo
Biosimilar Interna Pasando Jugo
Diabetic Macular Edema Interna Pasando Jugo
Diabetic Eye Awareness Interna Pasando Jugo
Diabetic Retinopathy Interna Pasando Jugo
Geographic Atrophy Interna Pasando Jugo
Imaging Interna Pasando Jugo
Inherited Retinal Diseases Interna Pasando Jugo
Ophthalmology Interna Pasando Jugo
RVO Interna Pasando Jugo
Retina Technology Interna Pasando Jugo
Retinal Surgery Interna Pasando Jugo
Uveitis Interna Pasando Jugo
Geographic Atrophy Interna Pasando Jugo
ISS 2026 highlights advances in ophthalmic imaging for retinal practice Interna Pasando Jugo
FLORetina: Inadvertent anti-VEGF interval increases during the COVID-19 pandemic Interna Pasando Jugo
Treating MacTel: First identify patient candidates and appropriate eye selection Interna Pasando Jugo
A medical fellow finds some magic at the AAO Annual Meeting Interna Pasando Jugo
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight Interna Pasando Jugo
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease Interna Pasando Jugo
FLORetina 2025: Long-term follow-up in pediatric gene therapy Interna Pasando Jugo
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management Interna Pasando Jugo
FLORetina 2025: Reframing retinal disease through the lens of choroidal health Interna Pasando Jugo
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage Interna Pasando Jugo
Martin David Harp Interna Pasando Jugo
Christina Y. Weng, MD, MBA, FASRS Interna Pasando Jugo
View All Interna Pasando Jugo
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO Interna Pasando Jugo
Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast Interna Pasando Jugo
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS Interna Pasando Jugo
The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD Interna Pasando Jugo
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME Interna Pasando Jugo
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD Interna Pasando Jugo
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice Interna Pasando Jugo
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice Interna Pasando Jugo
Integrating AI to manage DR in a primary care setting Interna Pasando Jugo
What to expect from virtual AAO 2020 Interna Pasando Jugo
View More Interna Pasando Jugo
Navigating geographic atrophy from biomarkers to bilateral therapy Interna Pasando Jugo
8 things to know about aflibercept 8 mg for retinal vascular disease Interna Pasando Jugo
Inside the mindset of an early adopter Interna Pasando Jugo
Challenges for young physicians treating patients with GA Interna Pasando Jugo
AAO highlight: Looking ahead to 2026 Interna Pasando Jugo
How AI is reshaping ophthalmology in 2025 and beyond Interna Pasando Jugo
Seeing the difference: Multimodal imaging for AMD and GA Interna Pasando Jugo
Ryan Livingston Interna Pasando Jugo
Lynda Charters Interna Pasando Jugo
Kevin Kunzmann Interna Pasando Jugo
Jeffry D. Gerson, OD, FAAO Interna Pasando Jugo
Theodore Leng, MD, MS Interna Pasando Jugo
Sheryl Stevenson Interna Pasando Jugo
Joshua Mali, MD Interna Pasando Jugo
Arshad M. Khanani, MD, MA, FASRS Interna Pasando Jugo
Modern Retina Staff Reports Interna Pasando Jugo
Jayanth Sridhar, MD Interna Pasando Jugo
Matt Hoffman Interna Pasando Jugo
Sheila Setork, OD Interna Pasando Jugo
About Interna Pasando Jugo
Advertise Interna Pasando Jugo
Editorial Interna Pasando Jugo
Contact Us Interna Pasando Jugo
Terms and Conditions Interna Pasando Jugo
Privacy Interna Pasando Jugo
Do Not Sell My Personal Information Externo Pasando Jugo
Home Interna Pasando Jugo

Palabras Clave SEO

Nube de Palabras Clave

cme track faao retinal cope view management more video fasrs

Consistencia de las Palabras Clave

Palabra Clave (Keyword) Contenido Título Palabras Claves (Keywords) Descripción Titulos
more 64
view 52
video 44
track 35
faao 24

Usabilidad

Url

Dominio : modernretina.com

Longitud : 16

Favicon

Genial, tu web tiene un favicon.

Imprimibilidad

No hemos encontrado una hoja de estilos CSS para impresión.

Idioma

Genial. Has declarado el idioma en.

Dublin Core

Esta página no usa Dublin Core.

Documento

Tipo de documento (Doctype)

HTML 5

Codificación

Perfecto. Has declarado como codificación UTF-8.

Validez W3C

Errores : 0

Avisos : 0

Privacidad de los Emails

Atención! Hemos encontrado por lo menos una dirección de correo electrónico en texto plano. Usa este protector antispam gratuito para ocultarla de los spammers.

HTML obsoleto

Genial, no hemos detectado ninguna etiqueta HTML obsoleta.

Consejos de Velocidad

Excelente, esta web no usa tablas.
Muy mal, tu web está usando estilos embenidos (inline CSS).
Genial, tu página web usa muy pocos ficheros CSS.
Muy mal, tu sitio usa demasiados ficheros JavaScript (más de 6).
Su sitio web se beneficia del tipo de compresión gzip. ¡Perfecto!

Movil

Optimización Móvil

Icono para Apple
Etiqueta Meta Viewport
Contenido Flash

Optimización

Mapa del sitio XML

¡Perfecto! Su sitio tiene un mapa del sitio en XML.

https://www.modernretina.com/sitemap.xml
https://www.modernretina.com/sitemap-news.xml

Robots.txt

https://modernretina.com/robots.txt

¡Estupendo! Su sitio web tiene un archivo robots.txt.

Herramientas de Analítica

¡Perfecto! Su sitio web tiene una herramienta de análisis.

   Google Analytics

PageSpeed Insights

Dispositivo
Categorias

Free SEO Testing Tool

Free SEO Testing Tool es una herramienta seo gratuita que te ayuda a analizar tu web